8-K: Inovio's INO-3107 BLA Accepted by FDA for RRP Treatment

Inovio Pharmaceuticals announced the FDA's acceptance of its Biologic License Application for INO-3107, an investigational immunotherapy for recurrent respiratory papillomatosis in adults, though accelerated approval eligibility is under review.

Summary

• The U.S. Food and Drug Administration (FDA) has accepted Inovio Pharmaceuticals, Inc.'s Biologic License Application (BLA) for INO-3107 for review.
• INO-3107 is an investigational immunotherapy intended for the treatment of recurrent respiratory papillomatosis (RRP) in adults.
• The FDA has designated the review classification as Standard and set a Prescription Drug User Fee Act (PDUFA) review goal date of October 30, 2026.
• The FDA is not currently planning to hold an advisory committee meeting to discuss this application.
• Inovio filed the BLA under the accelerated approval pathway, but the FDA noted a preliminary conclusion that the company has not submitted adequate information to justify eligibility for this pathway.
• Inovio plans to request a meeting with the FDA to discuss next steps to remain eligible under the accelerated approval program.
• The company is not currently planning to seek approval for INO-3107 under the traditional pathway.
• Clinical trial data from a Phase 1/2 trial (RRP-001) showed 72% of patients experienced a 50-100% reduction in surgeries in the first year after starting treatment.
• A retrospective study (RRP-002) involving 28 participants demonstrated an 86% reduction in surgeries at the end of the second 12-month period with no additional dosing, with half of those patients requiring no surgeries at all.
• Patients in RRP-001 had a median of 4 surgeries (range: 2-8) in the year prior to dosing.
• INO-3107 was well tolerated, with mostly low-grade (Grade 1) treatment-emergent adverse effects such as injection site pain and fatigue.
• INO-3107 has received FDA Orphan Drug and Breakthrough Therapy designations, European Commission Orphan Drug designation, and the UK Innovation Passport.

Sentiment

Score: 4

Explanation: While FDA acceptance of the BLA is a positive step, the significant hurdle regarding accelerated approval eligibility, coupled with the company's stated reluctance to pursue a traditional pathway, introduces substantial uncertainty and risk, tempering the overall positive news.

Positives

• The FDA has accepted the Biologic License Application (BLA) for INO-3107 for review, a significant regulatory milestone.
• A PDUFA review goal date of October 30, 2026, has been set, providing a clear timeline for a regulatory decision.
• The FDA is not currently planning to hold an advisory committee meeting, which can sometimes streamline the review process.
• INO-3107 has demonstrated strong clinical effectiveness, with 72% of patients seeing a 50-100% reduction in surgeries in the first year, increasing to 86% in the second year without additional dosing, and 50% requiring no surgeries in the second year.
• The treatment was well tolerated, with mostly low-grade adverse effects.
• INO-3107 has received multiple favorable designations, including FDA Orphan Drug and Breakthrough Therapy, European Commission Orphan Drug, and the UK Innovation Passport, highlighting its potential and addressing an unmet medical need.
• The CELLECTRA delivery device, integral to INO-3107, has received CE-marking in the EU.

Negatives

• The FDA has issued a preliminary conclusion that Inovio has not submitted adequate information to justify eligibility for the accelerated approval pathway.
• Inovio is not currently planning to seek approval for INO-3107 under the traditional pathway, which could leave the product without a clear path to market if accelerated approval is denied.

Risks

• Uncertainties inherent in pre-clinical studies, clinical trials, product development programs, and commercialization activities and outcomes.
• The availability of funding to support continuing research and studies to prove safety and efficacy of electroporation technology or develop viable DNA medicines.
• The ability to support the pipeline of DNA medicine products.
• The ability of collaborators to attain development and commercial milestones for licensed products.
• The adequacy of capital resources.
• The availability or potential availability of alternative therapies or treatments for targeted conditions that may be more efficacious or cost-effective.
• Issues involving product liability.
• Issues involving patents, including whether they or licenses to them will provide meaningful protection, are enforceable or defensible, infringe on rights of others, or can withstand claims of invalidity.
• The ability to finance or devote significant resources necessary to prosecute, protect, or defend proprietary rights.
• The level of corporate expenditures.
• Assessments of technology by potential corporate or other partners or collaborators.
• Capital market conditions.
• The impact of government healthcare proposals.
• No assurance that any product candidate in the pipeline will be successfully developed, manufactured, or commercialized.
• No assurance that clinical trial results will be supportive of regulatory approvals required to market products.
• The FDA's preliminary conclusion that adequate information has not been submitted to justify eligibility for the accelerated approval pathway for INO-3107.

Future Outlook

Inovio anticipates continuing collaboration with the FDA during the BLA review cycle for INO-3107. The company believes INO-3107 has the potential to expand treatment options for RRP patients and plans to request a meeting with the FDA to discuss next steps to remain eligible under the accelerated approval program, as it is not currently planning to seek approval via the traditional pathway.

Management Comments

• "We believe there remains a critical unmet need among patients diagnosed with this rare and devastating disease and that every RRP patient deserves access to a non-surgical treatment option that can work for them." Dr. Jacqueline Shea, President and Chief Executive Officer.
• "In clinical trials INO-3107 demonstrated it has the potential to expand the treatment options for RRP patients. This is based on a unique mechanism of action, clinical effectiveness and tolerability data and the simplicity of its patient centric treatment regimen, which does not require additional surgeries during the dosing window." Dr. Jacqueline Shea.
• "Every surgery matters to patients and we look forward to continuing to collaborate with the FDA during the BLA review cycle." Dr. Jacqueline Shea.

Industry Context

Recurrent Respiratory Papillomatosis (RRP) is a rare and debilitating disease primarily caused by HPV-6 and/or HPV-11, characterized by recurring papillomas in the respiratory tract. The current standard of care involves repeated surgeries, which carry risks and often do not prevent recurrence. Inovio's INO-3107, an investigational DNA medicine, aims to provide a non-surgical, T-cell mediated treatment option, addressing a significant unmet medical need for patients seeking to reduce surgical interventions and improve quality of life.

Comparison to Industry Standards

• The current standard of care for RRP is surgical removal of papillomas, which often leads to recurrence and repeated procedures. INO-3107 offers a potential non-surgical treatment option.
• INO-3107's mechanism of action, eliciting an antigen-specific T cell response against HPV-6 and HPV-11, is distinct from surgical interventions.
• Unlike other T cell generating platforms such as viral vectors, INOVIO's DNA medicines platform is designed to avoid anti-vector immunity, which could allow INO-3107 to maintain T cell response and overall efficacy over time.

Stakeholder Impact

• Shareholders face potential for significant share price volatility due to the BLA acceptance being tempered by the accelerated approval pathway concerns. Future share value will heavily depend on the outcome of regulatory discussions.
• Adult patients with RRP could potentially gain access to a new, non-surgical treatment option that may reduce the need for repeated surgeries and improve their quality of life, if INO-3107 ultimately receives approval.
• Healthcare professionals may have a new therapeutic tool for managing RRP, offering an alternative to the current surgical standard of care.
• Employees involved in the INO-3107 program will continue their work, but the regulatory uncertainty could impact long-term project stability and company outlook.

Next Steps

• Inovio plans to request a meeting with the FDA to discuss next steps to remain eligible under the accelerated approval program.
• The FDA intends to take action on the BLA by the PDUFA goal date of October 30, 2026.
• Inovio will continue to collaborate with the FDA during the BLA review cycle.

Key Dates

Recommendation

The FDA's acceptance of the BLA for INO-3107 is a positive milestone, indicating progress for a drug addressing a significant unmet medical need. However, the FDA's preliminary conclusion regarding the inadequacy of information for accelerated approval eligibility introduces substantial regulatory risk. The company's current stance of not pursuing a traditional approval pathway if accelerated approval is denied is a critical concern. Investors should hold to await the outcome of Inovio's discussions with the FDA regarding the accelerated approval pathway, as this will be a pivotal determinant of the drug's commercialization prospects and the company's future valuation.

Keywords

Inovio, INO-3107, FDA, BLA, RRP, Recurrent Respiratory Papillomatosis, DNA medicine, immunotherapy, HPV, accelerated approval, biotechnology, clinical trials, Orphan Drug, Breakthrough Therapy